EverythingALS announced NeuroSense Therapeutics Ltd. as a new collaborator in the effort to identify treatments and a cure for ALS. EverythingALS was founded in 2020 with the mission of bringing technological innovations and data science to support efforts—from care to cure—for people with ALS. The non-profit conducts technology-based research to help track progression of ALS to be utilized for clinical endpoints.

All of the organization's data and insights from research are made available as open science for researchers, pharmaceutical companies, and other potential partners to collaborate. NeuroSense is currently enrolling patients in PARADIGM, a Phase IIb double blind, placebo controlled, multicenter clinical trial to evaluate its lead drug candidate for ALS, PrimeC, in Israel and expects to begin patient enrollment in the US and EU this quarter. Top-line results are expected in Second Quarter 2023.

PrimeC was tested in a Phase IIa clinical study which successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration and demonstrated statistically significant changes in ALS-related biological markers. In addition to providing financial support for ongoing research projects, NeuroSense's strategic collaboration with EverythingALS will provide insight into patients' needs and allow the company to better serve the ALS community.